- Baiyunshan’s net income for the fiscal year was 4.06 billion yuan.
- The company’s revenue for the same period reached 75.52 billion yuan.
- There were more positive sentiments towards the company’s stock, with 4 buys, 1 hold and 1 sell.
A look at Guangzhou Baiyunshan Pharmaceutical Holdings Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Guangzhou Baiyunshan Pharmaceutical Holdings is a company that manufactures and sells Chinese patent medicine. They also sell Western and Chinese pharmaceutical products and medical apparatus. This company has been given high scores in various categories by Smartkarma, which indicates a positive long-term outlook.
The company has received a perfect score of 5 in both Value and Dividend, meaning that it is considered a good value investment and has a strong dividend payout. It also scored a 4 in Growth, Resilience, and Momentum, showing that it has potential for growth and is able to withstand economic challenges. This is good news for investors looking for a stable and profitable company to invest in.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
